Literature DB >> 19226634

Pharmacokinetics of liquiritigenin in mice, rats, rabbits, and dogs, and animal scale-up.

Hee E Kang1, Hye Y Jung, Yu K Cho, So H Kim, Se I Sohn, Seung R Baek, Myung G Lee.   

Abstract

Pharmacokinetics of liquiritigenin (LQ) and its two glucuronide metabolites, M1 and M2, in mice, rats, rabbits, and dogs and animal scale-up of the pharmacokinetic parameters of LQ were evaluated. After intravenous administration of LQ, the AUC (AUC(0-t)) values of LQ, M1, and M2 were proportional to LQ doses in all animals studied. Animal scale-up of some pharmacokinetic parameters of LQ was performed based on the parameters after its intravenous administration (20 mg/kg; in the linear pharmacokinetic range) to the four species. Linear relationships were obtained (r > 0.968) between log CL (or CL/f(u)) (L/h) and log species body weight (W) (kg) [CL (or CL/f(u)) = 3.29 (34.0) W(0.723 (0.789))] and log V(ss) (or V(ss)/f(u)) (L) and log W (kg) [V(ss) (or V(ss)/f(u)) = 0.340 (3.52) W(0.882 (0.948))]. Interspecies scale-up of plasma concentration-time data of LQ using apolysichron (complex Dedrick plots) resulted in similar profiles, and plasma concentration-time profile of humans were predicted using the well-fitted four animal data. Our results indicate that the LQ data obtained from laboratory animals could be utilized to generate preliminary estimates of the pharmacokinetic parameters of LQ in humans. These parameters can serve as guidelines for better planning of clinical studies. (c) 2009 Wiley-Liss, Inc. and the American Pharmacists Association

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19226634     DOI: 10.1002/jps.21702

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  6 in total

1.  Chiral analytical method development of liquiritigenin with application to a pharmacokinetic study.

Authors:  Casey L Sayre; Mandi Hopkins; Jody K Takemoto; Neal M Davies
Journal:  Biomed Chromatogr       Date:  2012-07-20       Impact factor: 1.902

2.  Biotransformation of Liquiritigenin into Characteristic Metabolites by the Gut Microbiota.

Authors:  Adili Keranmu; Li-Bin Pan; Jie Fu; Pei Han; Hang Yu; Zheng-Wei Zhang; Hui Xu; Xin-Yu Yang; Jia-Chun Hu; Hao-Jian Zhang; Meng-Meng Bu; Jian-Dong Jiang; Nian-Zeng Xing; Yan Wang
Journal:  Molecules       Date:  2022-05-10       Impact factor: 4.927

3.  Prediction of Deoxypodophyllotoxin Disposition in Mouse, Rat, Monkey, and Dog by Physiologically Based Pharmacokinetic Model and the Extrapolation to Human.

Authors:  Yang Chen; Kaijing Zhao; Fei Liu; Qiushi Xie; Zeyu Zhong; Mingxing Miao; Xiaodong Liu; Li Liu
Journal:  Front Pharmacol       Date:  2016-12-16       Impact factor: 5.810

4.  Stereospecific pharmacokinetic characterization of liquiritigenin in the rat.

Authors:  Samaa Alrushaid; Neal M Davies; Stephanie E Martinez; Casey L Sayre
Journal:  Res Pharm Sci       Date:  2017-06

5.  The Memory-Enhancing Effects of Liquiritigenin by Activation of NMDA Receptors and the CREB Signaling Pathway in Mice.

Authors:  Yong-Hyun Ko; Seung-Hwan Kwon; Ji-Young Hwang; Kyung-In Kim; Jee-Yeon Seo; Thi-Lien Nguyen; Seok-Yong Lee; Hyoung-Chun Kim; Choon-Gon Jang
Journal:  Biomol Ther (Seoul)       Date:  2018-03-01       Impact factor: 4.634

6.  Pharmacokinetics of DA-6886, A New 5-HT4 Receptor Agonist, in Rats.

Authors:  Dae Young Lee; Hee Eun Kang
Journal:  Pharmaceutics       Date:  2022-03-25       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.